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ABSTRACT: The aim of this study was to investigate the effects of alfacalcidol (1a(OH)D3: ALF) on bone collagen employing an
ovariectomized rat model. Thirty-five 16-week-old female Sprague-Dawley rats were divided into five groups: SHAM (sham-operatedþ
vehicle), OVX (ovariectomyþvehicle), and three ALF-treated groups, that is, ovariectomyþ 0.022mg/kg/day ALF, ovariectomyþ0.067
mg/kg/day ALF, and ovariectomyþ0.2mg/kg/day ALF. After 12 weeks of treatment, tibiae were subjected to histological, biochemical
and immunohistochemical analyses. Collagen matrices in OVX bone appeared as immature and poorly organized; however, with the
ALF treatment, it was improved in a dose-dependent manner. Contents of collagen and pyridinoline cross-link were decreased in OVX
compared with SHAM, but they increased to the level comparable to SHAM in ALF-treated groups. The total aldehyde, that is, a sum
of free and those involved cross-links, in the highest dose of ALF was significantly higher than the rest of the groups (p< 0.05). In
addition, the expression of lysyl oxidase was increased in the all ALF-treated groups compared with OVX (p<0.05). In conclusion, ALF
increases not only the amount of collagen but also enhances the maturation of collagen in ovariectomy-induced osteoporotic bones,
which likely contributes to the improvement of bone quality.  2014 The Authors. Journal of Orthopaedic Research. Published by
Wiley Periodicals, Inc. J Orthop Res 32:1030–1036, 2014.
Keywords: vitamin D; alfacalcidol; collagen; collagen cross-link; ovariectomized rats
Bone is a complex mineralized tissue, the principal
function of which is to resist mechanical forces. Bone
strength depends not only on the quantity of bone
tissue but also on its quality, which is characterized by
the geometry and shape of bones, the microarchitec-
ture of the trabecular bones, the mineral deposition,
and the collagen quality.1–3 Fibrillar type I collagen,
the predominant organic matrix component in bone,
functions as a 3-dimensional stable template to spa-
tially regulate mineralization.4 Crucial to this function
is the formation of covalent intermolecular collagen
cross-linking as it is the basis for the stability of the
fibrils. The type and quantity of collagen cross-links
are primarily determined by the extent of two post-
translational modifications, that is, hydroxylation and
oxidative deamination of the specific lysine (Lys)/
hydroxylysine (Hyl) residues, catalyzed by lysyl
hydroxylases (LHs; LH1-3) and lysyl oxidases (LOXs:
LOX, LOXL1-4), respectively.5 The maturation of
collagen cross-links could be regulated by the type and
extent of glycosylation of the helical cross-linking Hyl
residues.6 The specific cross-linking pattern appears to
be critically important for bone mineralization as
indicated by in vitro studies1,7 and its association with
Bruck syndrome, a rare form of osteogenesis imper-
fecta with congenital contractures.8
1a,25(OH)2D3, the biologically most active hormonal
form of vitamin D3, plays critical roles in many
physiological processes including calcium homeostasis,
bone metabolism, normal function of immune system,
and cancer prevention.9 The overall positive effect of
vitamin D3 on bone physiology has been known for a
century, since it prevents and cures rickets and
osteomalasia.10 Alfacalcidol (ALF), 1a(OH)D3, is a well
established and effective prodrug of 1a,25(OH)2D3.
11–16
Since it is readily converted to the latter without the
tightly regulated activation process in the kidney,17,18
it has been widely used to treat various metabolic
bone diseases.10,19,20 Though type I collagen gene is
considered as one of the 1a,25(OH)2D3 responsive
genes in osteoblasts derived from various species,21–24
it also regulates the post-translational modifications
of collagen in an osteoblastic cell culture system.25
However, the direct role of vitamin D3 on bone
collagen post-translational modifications and collagen
maturity in vivo is still not well understood. The
objective of this study was to investigate the effects of
various doses of ALF on the tibiae of ovariectomized




The protocol for the experiment was approved by the Institu-
tional Animal Care and Use of Teijin Pharma Ltd., and
conducted in accordance with accepted standards of humane
animal care. Thirty-five 10-week-old female Sprague-Dawley
rats (Charles River Laboratories Japan, Inc., Yokohama,
Japan) were housed in individual cages in a thermo neutral
environment (24 2˚C, humidity 55 15%) maintained on a
12-h light-dark cycle throughout the study (light on at 6 a.m.
and off at 6 p.m.). All animals received ad libitum access to
water and standard laboratory chow (1.25% calcium, 1.06%
phosphate, CE-2, Clea Japan, Inc. Tokyo, Japan) for the first
2 weeks to allow acclimation to the new environment. Rats
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underwent either ovariectomy or sham-operation under anes-
thesia with sodium pentobarbital (Kyoritsu Seiyaku, Co. Ltd.,
Tokyo, Japan) at 12 weeks of age. At 4 weeks post-surgery,
rats were divided into the following five groups:
1. SHAM (n¼7): sham-operated rats treated with
Vehicle (Saline/0.2%Triton X-100)
2. OVX (n¼7): ovariectomized rats treated with Vehi-
cle
3. 0.022mg ALF (n¼7): ovariectomized rats treated
with 0.022mg/kg/day
4. 0.067mg ALF (n¼7): ovariectomized rats treated
with 0.067mg/kg/day
5. 0.2mg ALF (n¼ 7): ovariectomized rats treated with
0.200mg/kg/day
Each drug was administrated orally five times a week for
12 weeks and the animals were sacrificed on the day after
finishing drug administration (28 weeks of age).
Serum Biochemistry and Bone Mineral Density (BMD) of Lumbar
Vertebrae
Upon sacrifice, blood (n¼ 7) was collected via the abdominal
aorta to measure serum calcium (Ca, mg/dL) concentrations
with a biochemistry automatic analyzer (Clinical analyzer
7180; HITACHI, Ltd., Tokyo, Japan). At 12 weeks after drug
administration, the BMD (g/cm2) of the fourth and fifth
lumbar vertebrae (L4, L5) (n¼ 7) were measured by dual-
energy X-ray absorptiometry (QDR-2000, Hologic, Inc., Bed-
ford, MA) under inhalation anesthesia with fluothane
(Takeda Pharmaceuticals, Co. Ltd., Osaka, Japan).
Picrosirius-Red (PSR) Staining
To investigate the organization and maturation of bone
collagen matrices in the SHAM, OVX, and ALF-treated
groups, the tibiae were collected and demineralized with
0.5M of ethylenediamine-tetraacetic acid (EDTA) (pH 7.4)
for 2 weeks, embedded in paraffin and sectioned into 5mm
thick slices. After hydration, the slides were stained with
0.1% solution of Sirius Red in saturated aqueous picric acid
(Electron Microscopy Sciences, Hatfield, PA) for 30min,
washed with 0.01N HCl, dehydrated and mounted. The
proximal metaphyses of tibiae were observed under a polar-
ized light microscopy (BX40 microscope, Olympus Co.,
Center Valley, PA) and photographed as previously
reported.26
Preparation of Bone Sample for Biochemical Analyses
Approximately one third of the proximal metaphyses of tibia
(n¼ 5) was dissected27 and soft tissues including periosteum
and bone marrow were removed. The samples were pulver-
ized to a fine powder under liquid N2 using a Spex Freezer
Mill (Spex, Inc., Metuchen, NJ). Pulverized samples were
washed with cold phosphate buffered saline (PBS) (pH 7.4),
then with cold double distilled water several times and
lyophilized. Aliquot of pulverized bone sample was deminer-
alized with 0.5M of EDTA for 2 weeks with several changes
of EDTA, washed with cold distilled water exhaustively and
lyophilized.28
Amino Acid and Cross-Link Analyses
Two to three milligrams of demineralized collagen were
reduced with standardized NaB3H4, hydrolyzed with 6N HCl
in vacuo, after flushing with N2 gas, for 22h at 105˚C. An
aliquot of each hydrolysate was subjected to amino acid
analysis on a high-performance liquid chromatography (HPLC)
system (Prostar 240/310, Varian, Walnut Creek, CA) with a
strong cation exchange column (AA-911, Transgenomic, San
Jose, CA).28 The amount of collagen relative to total proteins
was calculated as residues of hydroxyproline (Hyp) per 1,000
amino acids. The extent of Lys hydroxylation of collagen was
calculated as moles of Hyl/mole of collagen based on a value of
300 residues of Hyp per collagen molecule. The hydrolysates
with known amounts of Hyp were analyzed for cross-links on
the HPLC system with an AA-911 column (see above) linked to
a fluorescence detector (FP1520, Jasco Spectroscopic, Tokyo,
Japan) and a liquid scintillation analyzer (500TR series,
Packard Instrument, Meriden, CT).28 The cross-link precursor
aldehyde, that is, Hyl aldehyde (Hylald), the major reducible
cross-links, that is, dehydrodihydroxylysinonorleucine (deH-
DHLNL)/its keto amine, and dehydrohydroxylysinonorleucine
(deH-HLNL)/its keto amine, were analyzed as their reduced
forms, that is, dihydroxynorleucine (DHNL), dihydroxylysino-
norleucine (DHLNL), and hydroxylysinonorleucine (HLNL),
respectively. The non-reducible, mature cross-links, that is,
pyridinoline (Pyr) and deoxypyridinoline (d-Pyr), were also
analyzed simultaneously.28 All cross-links and aldehydes were
quantified as moles/mole of collagen.28 A total number of
aldehyde was calculated as a sum of DHNL, DHLNL, HLNL,
and 2 (Pyrþd-Pyr). The analyses were done in five indepen-
dent experiments.
Immunohistochemical Staining
To determine the relative distribution of LOX, immunohis-
tochemical analyses were performed within the tibia paraf-
fin sections of SHAM, OVX, and ALF-treated groups (see
PSR staining, above). The endogenous peroxidase activity
was quenched by incubating the slides in 0.3% H2O2 in
methanol for 30min. The nonspecific binding was blocked
using normal goat serum for 20min. The sections were
incubated overnight at 4˚C with primary antibody against
LOX (IMGENEX, San Diego, CA), which was diluted 1:200
in PBS. The specificity of immunoreactivity was confirmed
by using normal rabbit serum as negative controls. The
sections were incubated with biotinylated rabbit IgG (Vec-
tor Laboratories, Inc., Burlingame, CA) and then with
avidin-biotin-horseradish peroxidase complex (Vector Labo-
ratories, Inc.). After several washes with PBS, the sections
were incubated with 3, 30-diaminobenzidine substrate (Vec-
tor Laboratories, Inc.) to visualize the immunoreactivity.
The sections were observed under light microscopy (BX40
microscope, Olympus Co.). The area observed was 1.0–
2.0mm below the tibial growth plate and 200mm thickness
from the bone marrow side of cortical bone. LOX expression
was evaluated by counting the number of immunopositive
osteocytes/area. Data were collected from randomly select-
ed four sections per tibial bone from two animals in each
group.29
Statistical Analysis
All statistical evaluations were performed using Stat View
software (SAS Institute Inc., Cary, NC). Values were
expressed as means standard deviation in the text and the
tables, and the difference (in comparisons with SHAM,
OVX, 0.022mg ALF, 0.067mg ALF, and 0.2mg ALF) was
determined using analysis of variance (ANOVA) and Fish-
er’s PLSD. A p value of less than 0.05 was considered
significant.
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RESULTS
Serum Calcium Concentrations and BMD of Lumbar
Vertebra
ALF treatments raised the serum Ca levels in a dose-
dependent manner. Serum Ca level in OVX
(9.630.24mg/dL) was significantly decreased com-
pared with other groups (p<0.01). With the treatment
of ALF at 0.067mg/kg/day, the serum Ca level
(10.180.32mg/dL) was essentially the same as
SHAM (10.440.28mg/dL), and the serum Ca level in
the 0.2mg ALF group (11.05 0.31mg/dL) was signifi-
cantly higher than that in SHAM (p< 0.05) (Table 1).
In OVX, the BMD mean values of the lumbar
vertebrae (L4, L5) (0.200 0.014 g/cm2) were signifi-
cantly decreased compared with those in SHAM
(0.2490.017 g/cm2) at 16 weeks after surgery
(p<0.001). In the ALF-treated groups, the BMD
values increased in a dose-dependent manner, and in
the 0.067mg and 0.2mg ALF groups, the BMD values
(0.2340.017 g/cm2 and 0.248 0.022 g/cm2, respec-
tively) were significantly higher than those of OVX
(p<0.01) and comparable to those of SHAM (Table 1).
Histological Evaluation by PSR Staining
Figure 1 shows the representative images of the
proximal metaphysis of tibia stained with PSR ob-
served under polarized light. In SHAM (Fig. 1A), bone
collagen matrix stained yellow to red while that of
OVX (Fig. 1B) stained green to yellow. In the ALF-
treated groups (Fig. 1C–E), the color changed from
green to yellow and red in a dose dependent-manner.
The collagen matrices at the 0.2mg ALF group
(Fig. 1E) appeared to be well organized a finding
similar to SHAM.
Collagen Content and the Extent of Lys Hydroxylation
In OVX, the collagen content per protein (residue of
Hyp/1,000 total amino acids) was significantly lower
than those of SHAM and any of the ALF-treated
groups (p<0.001). The Hyp contents of the ALF-
treated groups, even those treated with the lowest
dose of ALF (0.022mg/kg/day), were all comparable to
those of SHAM showing no significant difference
among the groups (Table 2). The extent of Lys
hydroxylation in collagen (Hyl residues/300 residues of
Hyp) in OVX was higher than any other group
(p<0.05), and those of the 0.067 and 0.2mg ALF
groups were comparable with SHAM (Table 2).
Collagen Cross-Linking
Three reducible compounds associated with collagen
cross-links (DHNL: Reduced Hylald, DHLNL: Hylald X
Hyl and HLNL: Hylald X Lys or Lysald X Hyl), and two
non-reducible mature cross-links (Pyr: Hylald X Hylald
X Hyl and d-Pyr: Hylald X Hylald X Lys) were identified
in all samples. The results of collagen cross-link
analyses are summarized in Table 3. DHNL in the
0.2mg ALF group was significantly increased compared
with DHNL in SHAM, OVX and 0.022mg ALF groups
Table 1. Effect of ALF on Serum Ca and BMD at the
Lumbar Vertebra (L4, L5)
Serum Ca (mg/dL) BMD (g/cm2)
SHAM 10.44 (0.28)a 0.249 (0.017)
OVX 9.63 (0.24) 0.200 (0.014)
0.022mg ALF 10.09 (0.29),a,# 0.215 (0.010),$
0.067mg ALF 10.18 (0.32)a,# 0.234 (0.017)a
0.2mg ALF 11.05 (0.31),a 0.248 (0.022)a
The average values (n¼7) and SDs are shown. BMD, bone
mineral density. p< 0.05, p< 0.001, different from the value
of SHAM. aP< 0.01, different from the value of OVX. $p<0.05,
#p<0.01, different from the value of 0.2mg ALF.
Figure 1. Representative PSR staining of proximal metaphysis of tibiae in SHAM (A), OVX (B), 0.022mg ALF (C), 0.067mg ALF (D),
and 0.2mg ALF (E). Bone collagen matrix stained yellow to red in SHAM (Fig. 1A) and green to yellow in OVX (Fig. 1B). In the ALF-
treated groups (Fig. 1C–E), the color changed from green to yellow and red in a dose dependent-manner. The collagen matrices at the
0.2mg ALF group (Fig. 1E) appeared to be well organized.
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(p< 0.05). DHLNL showed no significant difference
among all of the groups examined. HLNL in the 0.2mg
ALF group was significantly increased when compared
with HLNL in all other groups examined (p< 0.05).
The non-reducible fluorescent cross-link, Pyr, in OVX
was significantly decreased when compared with that
of SHAM (p< 0.05), but Pyr in the 0.067 and 0.2mg
ALF groups was significantly higher than it was in
OVX (p< 0.01, p< 0.005, respectively). Pyr in the
0.2mg ALF group was significantly higher than that in
SHAM (p<0.01). d-Pyr showed no significant differ-
ence among any of the groups examined, though it
tended to be higher in the ALF-treated groups com-
pared with OVX. Table 4 shows the ratios of Pyr/d-Pyr
(the extents of Lys hydroxylation of the cross-links),
Pyrþd-Pyr/DHLNLþHLNL (the maturity of collagen
cross-links) and the total aldehyde (the sum of free
aldehyde and aldehyde involved in cross-links) of each
group. Pyr/d-Pyr in the 0.067 and 0.2mg ALF groups
was significantly higher than in OVX (p< 0.05).
Pyrþd-Pyr/DHLNLþHLNL in 0.2mg ALF group were
significantly increased in comparison to that in SHAM
and OVX (p<0.05, p<0.001, respectively). In 0.2mg
ALF group, Pyr/DHLNL was also significantly higher
than that in OVX (p<0.05) (data not shown). The total
aldehyde in 0.2mg ALF group was significantly higher
than in all other groups (p< 0.05).
LOX Expression in Tibia
Figure 2A–E shows representative images of immuno-
staining for LOX in SHAM, OVX, and ALF-treated
groups. No immunoreactivity was observed in the
respective negative controls (data not shown). The
results demonstrated that the levels of LOX protein in
tibiae in the ALF-treated groups were increased when
compared with those in OVX, and this was confirmed
by quantitative analysis of the intracellular expression
of LOX in osteocytes (p<0.05) (Fig. 2F). The intensity
of extracellular LOX staining also appeared to be
significantly greater in the ALF-treated groups
(Fig. 2C–E) when compared with that in OVX
(Fig. 2B).
DISCUSSION
ALF has been widely used for the treatment of
osteoporosis in certain countries. The effect of this
compound on bone formation has also been investigat-
ed in osteoporotic and bone fracture animal mod-
els.15,30–32 In our previous study using an osteoblastic
cell culture system, we examined the effects of 1a,25
(OH)2D3 on collagen cross-linking and related
enzymes, that is, LH1-3 and LOX, LOXL1-4. Those
results revealed that 1a,25(OH)2D3 directly regulated
collagen cross-linking in vitro by upregulating gene
expression of specific LHs and LOXs.25 Thus, we
conducted the present study to determine the dose-
effect of ALF on collagen matrix in osteoporotic bone,
specifically on collagen content, collagen cross-links
and collagen organization, by using an ovariectomized
rat model.
The results indicated that both BMD (Table 1) and
bone volume (Fig. 1) significantly diminished in OVX
but gradually increased with ALF treatment in a dose-
dependent manner. These are consistent with previous
reports.25,31 As for the bone matrix composition, the
biochemical analyses showed that bone matrix is
significantly less collagenous in OVX when compared
with control, indicating defective bone matrix composi-
tion in ovariectomized rats. However, with ALF treat-
ment including the one with the lowest dose of ALF,
that is, 0.022mg/kg/day, the level of collagen composi-
tion in bone matrix became comparable to control
(Table 2). This suggests that, even with a low dose of
ALF treatment, the composition of newly synthesized
bone matrix in OVX bone becomes comparable to
normal bone in terms of the collagen content.
Then, we examined the effect of ALF on the quality of
bone collagen in ovariectomized rats by histological,
immunohistochemical, and biochemical analyses. The
Table 2. Collagen Amount and the Extent of Lysine
Hydroxylation
Hyp/1,000 Hyl/Collagen
SHAM 83.5 (4.1) 41.5 (3.0)
OVX 72.2 (3.4) 43.8 (3.5)
0.022mg ALF 81.9 (2.4)c 39.5 (2.2)a
0.067mg ALF 82.2 (1.3)c 40.9 (1.8)a
0.2mg ALF 80.5 (1.4)b 41.3 (2.0)a
The average values (n¼ 5) and SDs in Hyp/1,000 are shown as
relative amounts in 1,000 total residues. The average values
(n¼5) and SDs in Hyl/collagen are shown as moles/mole of
collagen. Hyp, hydroxyproline; Hyl, hydroxylysine. p<0.05, p
< 0.001, different from the value of SHAM. ap<0.05, bp< 0.0l,
and cp<0.005, different from the value of OVX.
Table 3. Comparison of the Collagen Cross-Links
DHNL DHLNL HLNL Pyr d-Pyr
SHAM 0.088 (0.010) 0.863 (0.097) 0.297 (0.055) 0.207 (0.026) 0.155 (0.027)
OVX 0.090 (0.006) 0.890 (0.113) 0.301 (0.036) 0.175 (0.018) 0.142 (0.027)
0.022mg ALK 0.085 (0.018)# 0.836 (0.119) 0.306 (0.056)# 0.214 (0.022)# 0.169 (0.042)
0.067mg ALF 0.099 (0.009) 0.878 (0.097) 0.305 (0.037)# 0.238 (0.043)b,# 0.155 (0.027)
0.2mg ALK 0.105 (0.016),a 0.998 (0.217) 0.373 (0.051),a 0.276 (0.044),c 0.178 (0.030)
The average values (n¼5) and SDs are shown. The amounts of cross-links are expressed as moles/mole of collagen. DHNL,
dihydroxynorleucine; DHLNL, dihydroxylysinonorleucine; HLNL, hydroxylysinonorleucine; Pyr, pyridinoline; d-Pyr, deoxypyridinoline.
p<0.05, p<0.01, different from the value of SHAM. ap<0.05, bp< 0.01, and cp<0.001, different from the value of OVX. #p<0.05,
different from the value of 0.2mg ALF.
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result of PSR staining indicated that immature, poorly
organized collagen matrix seen in OVX became more
mature and organized with increasing ALF doses. This
suggests that higher doses of ALF better facilitate the
process of collagen maturation and organization in
ovariectomy-induced osteoporotic bones. The increased
levels of LOX expression in the ALF-treated groups also
support this notion, as LOX catalyzes the reaction that
initiates the process of collagen cross-linking. Since
collagen cross-linking plays crucial roles in bone forma-
tion, mineralization and maturation,1,33–35 we then ana-
lyzed collagen cross-links by biochemical means. Cross-
link analysis identified DHNL, DHLNL, HLNL, Pyr,
and d-Pyr in all groups indicating the major cross-
linking pathway to be the Hylald-derived, and this did
not change by ALF treatment. In OVX, the amounts of a
cross-link precursor aldehyde (DHNL) and immature
cross-links (DHLNL and HLNL) tended to increase
compared with those of SHAM though not statistically
significant. However, with the treatment of ALF at
0.2mg/kg/day, DHNL and HLNL were higher than those
of OVX and SHAM. Recently, Saito et al. reported that
DHLNL in the femoral bone of ovariectomized rats was
significantly lower than that in sham-operated rats.31
Table 4. The Ratio of Pyr/d-Pyr, PyrþdPyr/DHLNLþHLNL, and Total Aldehyde
Pyr/d-Pyr PyrþdPyr DHLNLþHLNL Total aldehyde
SHAM 1.354 (0.162) 0.720 (0.078) 1.972 (0.225)
OVX 1.252 (0.195) 0.662 (0.081) 1.915 (0.165)
0.022mg ALF 1.315 (0.254)# 0.768 (0.084) 1.994 (0.270)#
0.067mg ALF 1.546 (0.145)a 0.758 (0.101) 2.068 (0.186)#
0.2mg ALF 1.568 (0.251)a 0.859 (0.160),b 2.383 (0.244),a
The average values (n¼ 5) and SDs are shown. Total aldehyde: sum of DHNL, DHLNL, HLNL, and 2  (Pyrþd-Pyr). Pyr, pyridinoline;
d-Pyr, deoxypyridinoline; DHNL, dihydroxynorleucine; DHLNL, dihydroxylysinonorleucine; HLNL, hydroxylysinonorleucine. p<0.05,
different from the value of SHAM. ap<0.05, bp< 0.001, different from the value of OVX. #p< 0.05, different from the values of 0.2mg
ALF.
Figure 2. Immunohistochemical analysis for LOX. Representative distribution of LOX in the cortical bone 1.0–2.0mm distal below
the tibial growth plate and 200mm thickness from bone marrow side of SHAM (A), OVX (B), 0.022mg ALF (C), 0.067mg ALF (D), and
0.2mg ALF (E). Arrowheads indicate the areas of strong LOX expression in osteocyte cells. Magnification: 40. The bar represents
200mm. (F) Quantitative analysis of LOX expression (p< 0.05). The levels of LOX expression in tibiae in the ALF-treated groups were
increased when compared with those in OVX. The intensity of extracellular LOX staining also appeared to be significantly higher in
the ALF-treated groups (Fig. 2C–E) when compared with that in OVX (Fig. 2B).
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The difference between the results of their study and the
current one is not clear, but it could be due to aspects of
the experimental protocol such as the timing of sacrifice,
the strain of the rats used or the locations of bones
analyzed. As for the mature cross-links, Pyr in OVX was
significantly decreased compared with that in SHAM.
Pyr in 0.067 and 0.2mg ALF groups were significantly
increased compared with that of OVX. The cross-link
maturation assessed by Pyrþd-Pyr/DHLNLþHLNL in
0.2mg ALF group was significantly increased compared
with that in OVX and SHAM. In addition, Pyr/DHLNL
in 0.2mg ALF group was significantly increased com-
pared with that in OVX, and the total number of
aldehyde in 0.2mg ALF group was significantly higher
than in all other groups. These biochemical analyses
indicated that ALF treatment increased Hylald-derived
cross-links and the collagen maturation in ovariectomy-
induced osteoporotic bone, which was consistent with
our previous in vitro study.25 This is likely caused by
increased expression/activities of LOX and, possibly,
LOXL enzymes, resulting in the formation of highly
cross-linked and mature collagen fibrils.
We previously reported that, among LOX family
members, LOXL2 was most responsive to 1a,25
(OH)2D3.
25 It is not clear if this LOX isoform plays a
role on collagen cross-linking phenotype seen in the
ALF-treated groups in this study. The investigation of
the level of mRNA in the tissue could provide further
insight into the mechanisms of changing of cross-
linking profile in vivo. We have recently reported that
the pattern of glycosylation of the helical Hyl may
regulate the maturation of collagen cross-links.6 Since
the cross-link maturation is accelerated with a high
dose of ALF, ALF may affect collagen glycosylation as
well. In this study, we could not analyze another tri-
valent cross-link, pyrrole/deoxypyrrole, a condensation
product of Hylald, Lysald and Hyl/Lys36 due to its
inherent lability in acid hydrolysis. Though the quan-
titative analysis of this cross-link is still not estab-
lished, characterization of the pyrrole containing
cross-linked peptides by HPLC combined with mass
spectrometry could provide more comprehensive infor-
mation about the effect of ALF on collagen cross-links.
Further studies are warranted to address these issues.
Shiaishi et al.15 reported the effects of ALF (0.05, 0.1,
and 0.2mg/kg) on mechanical strength at cancellous
bone in lumber vertebra and cortical bone in femoral
midshaft. The results showed that bone strength in
ovariectomized rats without ALF treatments decreased
slightly compared with that in sham-operated rats
without ALF treatments, and ALF treatment in-
creased the bone strength of both cancellous bone in
lumber vertebra and cortical bone in a dose-dependent
manner. Interestingly, even with the lowest dose of
ALF (0.05mg/kg), bone strength was significantly
increased compared with that in sham-operated rats
treated with vehicle. Those results are consistent with
those of the current study, which demonstrate dose-
dependent increases in collagen cross-links and im-
proved collagen matrix maturation and organization
by ALF.
In conclusion, our study revealed that ALF effec-
tively normalizes the content of collagen, Lys hydrox-
ylation of collagen, collagen cross-linking and collagen
maturation/organization in bone. These data strongly
indicate that ALF enhances not only collagen deposi-
tion but also the maturation and stability of collagen
in osteoporotic bones, which likely contributes to the
improvement of bone quality.
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